Novimmune SA discovers and develops antibody-based drugs targeted for the treatment of inflammatory diseases, immune-related disorders and cancer. The company was founded by Bernard Mach in 1998 and is headquartered in Plan-les-Ouates, Switzerland.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

National Research Council of Canada, provides research & development. It services include research programs and collaboration opportunities, technical and advisory services, licensing opportunities and industrial research assistance program. The company was founded by Graham W. Burton and is headquartered in Ottawa, ON.

Kypha is an early-stage life sciences company developing leading-edge technology and clinically useful products to improve the way autoimmune and inflammatory disorders are monitored and treated. With a core team of nine, plus an extensive network of scientific advisors, clinical collaborators and business mentors, Kypha has leveraged Federal grants and raised more than $3 million in private capital since 2011 to advance its lead diagnostic product – Comp Act Dx – toward FDA clearance and commercial launch in early 2014. Comp Act Dx is a simple yet revolutionary test that quickly measures the level of inflammation in the body – such as that caused by traumatic injury or autoimmune disease – with an unprecedented combination of speed and accuracy. Comp Act Dx is designed to allow superior monitoring of at-risk patients by measuring changes in inflammation in near-real time, thereby aiding medical professionals in making earlier, more effective clinical intervention decisions.

Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration

Kymab is a clinical-stage biopharmaceutical company developing fully human monoclonal antibody therapeutics with a focus on immune-mediated diseases and immuno-oncology using its proprietary, integrated platforms collectively called IntelliSelect®. Kymab’s IntelliSelect Transgenic platforms contain a full diversity of human antibodies, making them the most comprehensive antibody platforms available. The company was founded in 2010 and is based in Cambridge, the United Kingdom.

Develops therapeutic and monitoring products to improve the outcome of organ transplantation

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

Guangzhou Hengshang Pharmaceutical Technology Co., Ltd., established on 2011-05-18, Business scope includes medical research and experimental development;Engineering and Technology Research and Experimental Development;drug development;Food Science and Technology Research Services;Stem Cell Technology Research,to develop;Human Science Research,to develop;Natural science research and experimental development;Biotechnology Development Services;Biotechnology Consulting,communication service;Biotechnology Transfer Services;Human Science Research Achievement Transfer Service;Biological control technology development services;Biological Control Technology Consulting,communication service;Biological control technology transfer service;Technology intermediary service;Science and Technology Information Consulting Services;Technology project agency service;Technology project bidding service;Science and technology project evaluation service;Scientific and technological achievements appraisal service;vocational skills training(Excludes vocational skills training programs that require license approval to operate);Business Management Consulting Services;Conference and Exhibition Services;Investment Advisory Services;

Adagene, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of novel antibody-based cancer immunotherapies. Its dynamic precision library platform is composed of the following proprietary technologies: NEObody, SAFEbody, and POWERbody. The company was founded by Ge Li and Pei Zhi Luo on February 25, 2011 and is headquartered in Suzhou, China.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

ALK is a global research-driven pharmaceutical company that focuses on prevention, diagnosis and treatment of allergies. Since 1923 ALK has been working to improve the quality of life for allergy patients by developing drugs that target the cause of allergy. ALK is the world leader in allergy immunotherapy - a unique treatment of the cause of allergies. The treatment induces a protective immune response that provides a sustained reduction of allergy symptoms and reduces the risk of developing asthma. ALK provides allergy immunotherapy products as injections, sublingual drops and sublingual tablets, which is the newest, best documented and most convenient treatment for patients. The portfolio of products also includes an adrenaline used to treat severe allergic reactions (anaphylactic shock). ALK invests annually approx. 20% of revenue in research that aims to develop new, evidence-based allergy immunotherapy. Research and development pipeline includes sublingual allergy immunoterapy tablets against ragweed, house dust mite and tree pollen allergy. ALK has signed partnership agreements with Merck and Torii Pharmaceutical, concerning the development, registration and commercialisation of tablets in Northern America and Japan. ALK has approx. 1,800 employees with subsidiaries, production facilities and distributors worldwide. The company headquarters is in Denmark and is listed on NASDAQ OMX Copenhagen (OMX: ALK B). In 2013 the turnover was more than DKK 2.2 billion (EURm 300).

Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Its product pipeline include Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

ALK is a healthcare service provider. They offer products and services via a web shop to help people manage their allergies. It also provides treatment for respiratory allergies that works by treating the underlying cause of the allergy.

Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA.

CytoMedical Design Group LLC develops and distributes stem cell tools and technologies to the cord blood banking and cellular therapy markets. Its lead product, the PrepaCyte CB Processing System, separates total nucleated cells and stem cells from cord blood for banking and storage. The company was founded by Michael Haider, Carol Buchert, and Daniel Collins in 2011 and is headquartered in St. Paul, MN.